RS
CTKB icon

R Squared’s Cytek Biosciences CTKB Stock Holding History

R Squared’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
+35,412
New +$151K 0.08% 365
2025
Q1 		– Sell
-280
Closed -$1.82K – 583
2024
Q4 		$1.82K Buy
+280
New +$1.67K ﹤0.01% 1472

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

R Squared's CTKB Position: Q2 2026 in Review

R Squared opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 35,412 shares worth $157K. The stake represents 0.08% of the portfolio and ranks #365 among its holdings. This is a return to the name: R Squared previously reported a position in CTKB as recently as Q4 2024.

R Squared first reported a position in CTKB in Q4 2024 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • R Squared held 35,412 shares of Cytek Biosciences worth $157K as of Q2 2026.
  • Cytek Biosciences was a new R Squared position in Q2 2026.
  • Cytek Biosciences made up 0.08% of R Squared's portfolio in Q2 2026, its #365 holding.
  • R Squared first reported a position in Cytek Biosciences in Q4 2024 and has held it in 2 quarters since.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.